Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(3 years from now) | |
US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(4 years from now) | |
US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(9 years from now) |
Drugs and Companies using INGENOL MEBUTATE ingredient
Market Authorisation Date: 23 January, 2012
Treatment: Use of ingenol mebutate to treat actinic keratosis; Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate
Dosage: GEL;TOPICAL
16
United States
4
European Union
2
EA
2
Japan
2
Korea, Republic of
2
United Kingdom
1
Spain
1
Denmark
1
Poland
1
Brazil
1
Canada
1
Norway
1
New Zealand
1
Cyprus
1
Israel
1
Portugal
1
Slovenia
1
Mexico
1
Australia
1
South Africa
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic